Safety and efficacy of therapeutic early onset granulocyte transfusions in pediatric patients with neutropenia and severe infections

Sachs, Ulrich J.; Reiter, Alfred; Walter, Tobias; Bein, Gregor; Woessmann, Wilhelm

doi:10.1111/j.1537-2995.2006.00996.x

Cited by 77 publications

(77 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17 Recent studies of therapeutic granulocyte transfusions for neutropenic infections in patients with leukemia and/or undergoing HSCT have shown survival rates of 31-81%; in patients with invasive fungal infections, the survival rates range from 20-80%. These studies, summarized in Table 4, [1][2][3][4][5][6][18][19][20][21][22][23][24][25] vary in the definition of invasive fungal infections, the timing of initiating granulocyte therapy, the cell dose of granulocytes transfused, and the number of granulocyte doses given. One study was randomized, but only 60% of patients were actually neutropenic prior to receiving granulocytes, and 44% of patients randomized to the granulocyte arm received only one or two transfusions before neutrophil recovery.…”

Section: Discussionmentioning

confidence: 99%

Granulocyte transfusions in severe aplastic anemia: an eleven-year experience

Quillen¹,

Wong

Scheinberg

et al. 2009

Haematologica

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Granulocyte transfusions in severe aplastic anemia: an eleven-year experience

Quillen¹,

Wong

Scheinberg

et al. 2009

Haematologica

View full text Add to dashboard Cite

“…Isolation of CD177 Proteins from Human NeutrophilsGranulocyte concentrates were obtained from healthy volunteers by a standard leukapheresis procedure (34). Twelve hours prior to apheresis, all volunteers received 7.5 g per kilogram bodyweight of human recombinant granulocyte-colony-stimulating factor (ChugaiPharma, Frankfurt am Main, Germany), as approved by the local ethics committee.…”

Section: Methodsmentioning

confidence: 99%

The Neutrophil-specific Antigen CD177 Is a Counter-receptor for Platelet Endothelial Cell Adhesion Molecule-1 (CD31)

Sachs

Andrei-Selmer

Maniar

et al. 2007

Journal of Biological Chemistry

Self Cite

208

199

View full text Add to dashboard Cite

Human neutrophil-specific CD177 (NB1 and PRV-1) has been reported to be up-regulated in a number of inflammatory settings, including bacterial infection and granulocyte-colonystimulating factor application. Little is known about its function. By flow cytometry and immunoprecipitation studies, we identified platelet endothelial cell adhesion molecule-1 (PECAM-1) as a binding partner of CD177. Real-time proteinprotein analysis using surface plasmon resonance confirmed a cation-dependent, specific interaction between CD177 and the heterophilic domains of PECAM-1. Monoclonal antibodies against CD177 and against PECAM-1 domain 6 inhibited adhesion of U937 cells stably expressing CD177 to immobilized PECAM-1. Transendothelial migration of human neutrophils was also inhibited by these antibodies. Our findings provide direct evidence that neutrophil-specific CD177 is a heterophilic binding partner of PECAM-1. This interaction may constitute a new pathway that participates in neutrophil transmigration.CD177 (NB1 and PRV-1) is a 58-to 64-kDa glycosylphosphatidylinositol-anchored glycoprotein expressed exclusively by neutrophils, neutrophilic metamyelocytes, and myelocytes, but not by any other blood cells (1, 2). We and others elucidated its primary structure by sequencing the NB1 and PRV-1 genes, which later turned out to be two alleles of a single CD177 gene (3-5). The surface expression of CD177 is unique in that only a subpopulation of neutrophils expresses this protein on the cell surface, with the mean size of the CD177-positive subpopulation ranging from 45% to 65% (2, 6).CD177 has been well studied as a target antigen in immunemediated disorders. During pregnancy, women with a CD177 null phenotype are prone to produce alloantibodies against CD177 that cross the placenta, react with fetal neutrophils, and cause neutropenia of the newborn. This mechanism let to the initial discovery of the NB1 antigen in 1971 (7). Alloantibodies to CD177, present in blood products obtained from immunized donors, have also been implicated as mediators of transfusionrelated acute lung injury (8).Although well characterized as an immunotarget, the function of CD177 is largely unknown. It has been reported that CD177 is up-regulated on the neutrophil surface upon stimulation, including during severe bacterial infections, and following granulocyte-colony-stimulating factor treatment (9). In addition, antibody-mediated clustering of CD177 primes the N-formyl-methionyl-leucyl-phenylalanine (fMLP) 3 -activated respiratory burst reaction of the neutrophil (8). Taken together, these observations make it reasonable to suppose that CD177 may be involved in processes of neutrophil-mediated host defense. One preliminary study suggests a participation of CD177 in neutrophil-endothelial cell interaction (10). The latter observation is in line with the fact that CD177, as a member of the leukocyte antigen-6 superfamily, shares a similar structure with the urokinase plasminogen activator receptor (11). Urokinase plasminogen activator receptor is expr...

show abstract

“…This result is superior to that in the past in similar patients who did not receive granulocyte transfusion treatment, and is in agreement with more recently published reports. 3,5,[40][41][42] Prophylactic granulocyte transfusion has already been reported to be beneficial in such patients. 8,9,40,43,44 None of our patients treated pre-emptively showed progression of prior lowgrade (fungal) infection during the period of neutropenia after SCT conditioning.…”

mentioning

confidence: 99%

Granulocyte concentrates: prolonged functional capacity during storage in the presence of phenotypic changes

Drewniak¹,

Boelens²,

Vrielink³

et al. 2008

Haematologica

View full text Add to dashboard Cite

BackgroundGranulocyte transfusion has been proposed as a bridging therapy for patients with prolonged periods of chemotherapy-induced neutropenia, who suffer from severe fungal and bacterial infections. To recover, adequate numbers of granulocytes are required when the patients are refractory to standard treatment. The aim of this study was to assess the functional characteristics and efficacy of granulocyte colony-stimulating factor/dexamethasone-mobilized granulocytes used for transfusions.

show abstract

Safety and efficacy of therapeutic early onset granulocyte transfusions in pediatric patients with neutropenia and severe infections

Cited by 77 publications

References 24 publications

Granulocyte transfusions in severe aplastic anemia: an eleven-year experience

Granulocyte transfusions in severe aplastic anemia: an eleven-year experience

The Neutrophil-specific Antigen CD177 Is a Counter-receptor for Platelet Endothelial Cell Adhesion Molecule-1 (CD31)

Granulocyte concentrates: prolonged functional capacity during storage in the presence of phenotypic changes

Contact Info

Product

Resources

About